AHSCX — Alger Health Sciences Fund
Data updated: 2026-06-26
AHSCX — Alger Health Sciences Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $60.86M AUM · 1.96% expense ratio · 21.6% 1-yr return. From SEC regulatory filings.
AHSCX Fund Overview
AHSCX — Alger Health Sciences Fund is a US mutual fund managed by Alger Funds, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Alger Funds
- Category: United States Health Care Equity
- Assets under management: $60.86M
- 1-year return: 21.6%
- Ticker: AHSCX
- SEC CIK: 0000003521
- SEC series ID: S000009164
- Share class ID: C000024917
AHSCX Holdings
Top 10 holdings of Alger Health Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Teva Pharmaceutical Industries Ltd. | 4.58% |
| Impulse Dynamics Ireland | 4.57% |
| Forte Biosciences, Inc. | 4.28% |
| Arrowhead Pharmaceuticals, Inc. | 4.04% |
| Welltower, Inc. | 3.23% |
| Cardinal Health, Inc. | 3.22% |
| Johnson & Johnson | 2.99% |
| Twist Bioscience Corp. | 2.93% |
| Merck & Company, Inc. | 2.88% |
| Nektar Therapeutics | 2.66% |
AHSCX Portfolio Allocation
Asset-class allocation of Alger Health Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.0% |
| Cash & Equivalents | 1.4% |
AHSCX Performance
Total returns for AHSCX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -0.8% |
| 1 year | 21.6% |
| 3 years (annualised) | 2.9% |
| 5 years (annualised) | 1.6% |
AHSCX Risk Information
Risk metrics for AHSCX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.0%
AHSCX Costs and Fees
AHSCX costs about $196 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.96%
- Gross expense ratio: 1.96%
- Portfolio turnover: 289%
- Brokerage commissions: 32.15 bps of average net assets (SEC N-CEN)
AHSCX Cashflows
Over the 12 months to 2026-04, Alger Health Sciences Fund had net outflows of $20.90M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$924.72K |
| 2026-03 | −$1.40M |
| 2026-02 | −$826.83K |
| 2026-01 | −$1.63M |
| 2025-12 | −$2.06M |
| 2025-11 | −$910.82K |
AHSCX Debt Constituents
No individual debt constituents are reported in Alger Health Sciences Fund's latest SEC N-PORT filing.
AHSCX Prospectus and SEC Filings
Official Alger Health Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.